Omega-3 ingredient innovations are bringing life back to a market still in recovery.
A new meta-analysis published by the U.S. Agency for Healthcare Research and Quality finds evidence that omega-3 consumption lowers triglycerides and raises HDL cholesterol, but its findings on other cardiovascular health markers are less strong.
Re-esterified omega-3 consumption was found to significantly improve tear osmolarity, tear beak-up time, and the ocular surface disease index in a new study.
Rimfrost’s Sublime PL60 krill oil, which debuted last fall, features a phospholipid content of up to 60% and high levels of choline, astaxanthin, and omega-3 DHA and EPA.
Aker BioMarine has shared data suggesting krill oil’s share of the omega-3 market increased from 12% in 2012 to 20% in 2016.
Finished products containing EPA and DHA omega-3s posted a worldwide market value of $31.4 billion in 2015, with Asia accounting for 36% of the market, GOED says.
Fish oil–derived EPA and DHA were also found to attenuate strength loss and muscle soreness following exercise, according to researchers.
Fish oil–derived DHA was found to be more effective than EPA at modulating blood lipids and specific markers of inflammation in a new human clinical study.
FDA has determined Amarin’s Vascepa EPA omega-3 drug is eligible for new chemical entity (NCE) marketing exclusivity. Will it impact omega-3 supplements?
Contract testing lab OmegaVeritas says it has created the first third-party testing process to authenticate krill oil.